SULM – Schweizerische Union für Labormedizin | Union Suisse de Médecine de Laboratoire | Swiss Union of Laboratory Medicine

Sie sind hier | Vous êtes ici:

İlker Durak1 , Hasan Biri2 , Erdinç Devrim1 , İmge Ergüder1

1Ankara University School of Medicine, Biochemistry Department, Sıhhıye, Ankara- Turkey., 2Gazi University School of Medicine, Urology Department, Ankara- Turkey.

Adenosine deaminase (ADA) is a key enzyme in the degradation of adenine nucleotides (1). It has been reported that some food components affect human tumor cell activities. Inhibitory activities of garlic, tomato and grape extract were observed in several kinds of human cancers (2, 3, 4). In the present study, possible effects of garlic, tomato and grape extracts on ADA activities were investigated in cancerous and non cancerous human urinary bladder tissues.
Methods: Twenty tissue samples were obtained from 10 patients with colon cancer. Of the 20 samples, 10 were removed from cancerous region and 10 from non cancerous adjacent region. ADA activities were measured in the tissues with and without pre incubation with equal amounts of tomato juice, garlic and black grape extracts for 12 h.
Results: No change was observed between ADA activities (mIU/mg) of cancerous and non cancerous tissues (7.56±4.538 vs. 8.66±3.05, p>0.05). Tomato exerted no inhibition on the ADA activities in both tissues (8.65±5.33 vs. 7.22±2.42, p>0.05). However, garlic and black grape extracts significantly affected the activity. In this regard, ADA activities in the cancerous tissues were completely abolished by garlic and grape extracts, and those in non cancerous tissues were significantly reduced by garlic (1.60±0.60) and completely abolished by grape extract.
Summary-Conclusion: Results suggest that tomato has no inhibition potential on the ADA activity of human bladder tissue, but both garlic and black grape significantly inhibit the activity. This might be rational basis for the use of the garlic and black grape in the supportive cancer therapy.
1. Lizuka H, Koizumi H, Kamigaki K. J Dermatol 1981;8:91-5.
2. Chung JG. Drug Chem Toxicol 1999;22:343-58.
3. Okajima E, Tsutsumi M, Ozono S. Jpn J Cancer Res 1998;89:22–9.
4. Singh RP, Tyagi AK, Dhanalakshmi S. Int J Cancer 2004;108:733-40.


07. & 08.03.2019: Swiss eHealth Forum - Digitales Gesundheitswesen – Hope and > mehr


pipette 06/2018: Die Analyse der Darmflora | Analyse du microbiote

Aktuelle Ausgabe als E-Paper lesen


17.12.2018: Cheflaboranten/in 80%, (HFR) Tafers